Therefore, in the absence of other pathogenic evidence (rarity, case-control studies, presence in ataxia telangiectasia patients in the case of ATM, etc.), these ATM variants cannot be considered loss-of-function/pathogenic variants based on splicing data alone. This evidence concerns the gene ATM and ataxia telangiectasia.